Novavax shifts focus from COVID vaccine sales to licensing its vaccine tech globally.

Novavax CEO John Jacobs outlined the company's transformation from focusing solely on commercializing its COVID vaccine to now licensing its nanoparticle protein-based vaccine technology and Matrix-M adjuvant to global partners. This strategy leverages partners' infrastructure to develop diverse vaccine portfolios while Novavax continues selective R&D on its own assets. The shift aims to expand the use of their technology and improve vaccine performance and cost efficiency worldwide.